Selective androgen receptor modulator and methods of use thereof
This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
1. A method of treating, reducing the severity, reducing the incidence, or reducing the pathogenesis of Duchenne muscular dystrophy in a subject in need thereof, comprising administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula S-(III):
or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.
2. The method of claim 1 , wherein said administering comprises administering a pharmaceutical composition comprising said compound and/or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof; and a pharmaceutically acceptable carrier.
3. The method of claim 1 , wherein said method further increases the physical function of said subject.
4. The method of claim 1 , wherein said method further increases the quality of life of said subject.
5. The method of claim 1 , wherein said method increases the survival of said subject.
6. The method of claim 1 , wherein said method further improves symptoms of cardiomyopathy or respiratory function.
7. A method of increasing the physical function of a subject suffering from Duchenne muscular dystrophy, comprising administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula S-(III):
or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.
8. A method of increasing the quality of life of a subject suffering from Duchenne muscular dystrophy, comprising administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula S-(III):
or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.
9. A method of increasing the survival of a subject suffering from Duchenne muscular dystrophy, comprising administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula S-(III):
or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.
10. A method of treating, reducing the severity, reducing the incidence, or reducing the pathogenesis of Becker muscular dystrophy in a subject in need thereof, comprising administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula S-(III):
or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.
11. The method of claim 10 , wherein said administering comprises administering a pharmaceutical composition comprising said compound and/or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof; and a pharmaceutically acceptable carrier.
12. The method of claim 10 , wherein said method further increases the physical function of said subject.
13. The method of claim 10 , wherein said method further increases the quality of life of said subject.
14. A method of treating, reducing the severity, reducing the incidence, or reducing the pathogenesis of myotonic dystrophy, limb-girdle muscular dystrophy, facioscapulhumeral muscular dystrophy, congenital muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, or Emery-Dreifuss muscular dystrophy in a subject in need thereof, comprising administering to said subject a selective androgen receptor modulator (SARM) compound represented by the structure of formula S-(III):
or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.
15. The method of claim 14 , wherein said administering comprises administering a pharmaceutical composition comprising said compound and/or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof; and a pharmaceutically acceptable carrier.
16. The method of claim 14 , wherein said method further increases the physical function of said subject.
17. The method of claim 14 , wherein said method further increases the quality of life of said subject.